No Detail Found!

Effect of levocarnitine plus iron sucrose on nutritional status and life cycle in uremic patients with renal anemia

Author(s)
Li Ren Department of Nephrology, Shaanxi Provincial Nuclear Industry 215 Hospital,Xianyang, Shaanxi,China
Jun Wu Department of Nephrology, Shaanxi Provincial Nuclear Industry 215 Hospital,Xianyang, Shaanxi,China
Yanqin Shi Department of Nephrology, Shaanxi Provincial Nuclear Industry 215 Hospital,Xianyang, Shaanxi,China
Dong Li Department of Nephrology, Shaanxi Provincial Nuclear Industry 215 Hospital,Xianyang, Shaanxi,China
Gelu Huang Department of Nephrology, Shaanxi Provincial Nuclear Industry 215 Hospital,Xianyang, Shaanxi,China
Nana Meng Department of Nephrology, Shaanxi Provincial Nuclear Industry 215 Hospital,Xianyang, Shaanxi,China
Abstract
Research team believes that Levocarnitine (L-carnitine) combined with Iron sucrose (IS) has a more significant positive effect on the nutritional status and lifespan of uremic patients with renal anemia and has carried out research and demonstration based on this. First, research team selected 90 uremic patients with renal anemia admitted to our hospital from February 2019 to February 2022 and randomized them to an experimental group (n=45) and a control group (n=45) that were given L-carnitine+IS and L-carnitine, respectively. The clinical efficacy and adverse reactions of the two groups of patients were counted and fasting venous blood was collected before and after treatment to test nutrient proteins, calcium and phosphorus metabolism and renal function. In addition, 1-year prognostic follow-up was performed to count the prognostic survival of the patients. The results of the study showed that the clinical efficacy of the experimental group was better than that of the control group and the nutritional protein, calcium and phosphorus metabolism and renal function were better after treatment (P0.05). Prognostic follow-up showed that there was no difference in the prognostic overall survival rate between the two groups (P>0.05), but the median survival of the experimental group was prolonged compared with the control group (P<0.05). In conclusion, L-carnitine combined with IS effectively ameliorated the anemia status of patients, improved their nutritional status and prolonged their median survival.
Publication Details
Page(s) 745-750
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Nutritional status, Life Cycle, Iron sucrose, Uremia, levocarnitine
References
Abdel-Kader K .2022 .Symptoms with or because of kidney failure?. Clin. J. Am. Soc. Nephrol., 17(4) : 475-477.
Abe K,Fujita M,Hayashi M,Takahashi A,Ohira H A .2021 .The efficacy of levocarnitine treatment in relieving fatigue in patients with cirrhosis but without overt hepatic encephalopathy. Intern. Med, 60(22) : 3533-3542.
Arastu AH,Elstrott BK,Martens KL,Cohen JL,Oakes MH,Rub ZT,Aslan JJ,DeLoughery TG,Shatzel J .2022 .Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions. JAMA Netw, 5(3) : e224488.
Avdonin PP,Blinova MS,Generalova GA,Emirova KM,Avdonin PV .2023 .The role of the complement system in the pathogenesis of infectious forms of hemolytic uremic syndrome. , 14(1) : 39.
Boyer O and Niaudet P .2022 .Hemolytic-Uremic Syndrome in Children. , 69(6) : 1181-1197.
Calo LA,Vertolli U,Davis PA,Savica V .2012 .L carnitine in hemodialysis patients. Hemodial. Int., 16(3) : 428-434.
Dave CV,Brittenham GM,Carson JL,Setoguchi S JL .2022 .Risks for anaphylaxis with intravenous iron formulations: A retrospective cohort study. Ann. Intern. Med, 175(5) : 656-664.
He H and Xie Y .2021 .Alteration of intestinal microflora in uremia patients with or without blood purification. Niger. J. Clin. Pract, 24(8) : 1133-1137.
Kashani K,Cozzolino MG,Massy ZA,Blankestijn PJ,Stenvinkel P,Rosner MH,Ronco C .2023 .Proposal for a new classification of solutes of interest in uremia and hemodialysis. Blood Purif, 52(3) : 233-241.
Koekkoek KWA,Berger MM .2023 .An update on essential micronutrients in critical illness. Curr. Opin. Crit. Care., 29(4) : 315-329.
Macdougall IC,Comin-Colet J,Breymann C,Spahn DR,Koutroubakis IE .2020 .Iron sucrose: A wealth of experience in treating iron deficiency. Adv. Ther., 37(5) : 1960-2002.
Meijers B,Zadora W,Lowenstein J .2024 .A historical perspective on uremia and uremic toxins. Toxins, 16(5) : .
Michael M,Bagga A,Sartain SE,Smith RJH SE .2022 .Haemolytic uraemic syndrome. Lancet., 400(10364) : 1722-1740.
Pagano G,Pallardo FV,Porto B,Fittipaldi MR,Lyakhovich A,Trifuoggi M .2020 .Mitoprotective clinical strategies in type 2 diabetes and fanconi anemia patients: Suggestions for clinical management of mitochondrial dysfunction. Antioxidants, 9(1) : .
Rehman S,Farhan M,Kumar S,Sarfraz MR,Naveed A,Khan MT,Huq H MT .2025 .Efficacy of intravenous versus oral administration of levocarnitine in maintenance hemodialysis patients: A randomized controlled trial investigating therapeutic approaches to renal anemia. Health Sci. Rep, 8(1) : e70297.
Sindone A,Doehner W,Comin-Colet J .2023 .Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency. ESC Heart Fail., 10(1) : 44-56.
Song MJ,Park CH,Kim H,Han S,Lee SH,Lee DH,Chung JH .2023 .Carnitine acetyltransferase deficiency mediates mitochondrial dysfunction-induced cellular senescence in dermal fibroblasts. Aging Cell., 22(11) : e14000.
Wang P,Guo C,Pan H,Chen W,Peng D .2021 .Iron sucrose: A double-edged sword in high phosphate media-induced vascular calcification. Calcif. Tissue Int, 108(6) : 798-807.
Yan J,Winkelmayer WC,Walther CP .2023 .Iron sucrose and blood pressure patterns during hemodialysis. Am. J. Kidney Dis, 81(6) : 629-631.
0

Citations

0

Downloads

69

Views